Amisulpride Toxicity: Symptoms and Management
In amisulpride overdose (>1200 mg/day oral), immediately initiate cardiac monitoring with continuous ECG for at least 16 hours and treat severe extrapyramidal symptoms; there is no specific antidote and hemodialysis is ineffective 1.
Signs and Symptoms of Toxicity
Amisulpride toxicity manifests through two primary organ systems due to its dopamine-2 (D2) receptor antagonism:
Cardiovascular Toxicity
- QT interval prolongation (often >500 ms in overdose)
- Torsades de pointes (potentially fatal ventricular arrhythmia)
- Bradycardia (can occur even at therapeutic doses)
- Hypotension
- Rate-dependent bundle branch block 1, 2
The cardiovascular effects show a dose-dependent relationship, with significant QT prolongation occurring at supratherapeutic doses. At the 10 mg IV dose used for postoperative nausea, the mean QTc prolongation is only 8.0 milliseconds 3, but oral doses above 1200 mg/day produce clinically dangerous prolongation 1.
Neuropsychiatric Toxicity
- Sedation progressing to coma
- Seizures
- Dystonic reactions
- Extrapyramidal symptoms (acute dystonias, akathisia, parkinsonism)
These neuropsychiatric effects result from excessive D2 receptor blockade in the central nervous system 1.
Management Algorithm
Immediate Actions (First 30 minutes)
- Obtain 12-lead ECG immediately upon presentation
- Establish continuous cardiac monitoring
- Assess airway, breathing, circulation - intubate if comatose or seizing
- Obtain IV access and draw baseline labs (electrolytes, particularly potassium and magnesium)
Cardiac Management
- Continue ECG monitoring for minimum 16 hours after ingestion, or longer if QT remains prolonged 2
- Correct electrolyte abnormalities aggressively (maintain K+ >4.0 mEq/L, Mg2+ >2.0 mg/dL)
- If torsades de pointes develops: administer IV magnesium sulfate 2g over 1-2 minutes, consider overdrive pacing
- Do NOT attempt hemodialysis - amisulpride is weakly dialyzed and ineffective for drug removal 1
Neurological Management
- For severe extrapyramidal symptoms:
- Benztropine 1-2 mg IV/IM or diphenhydramine 25-50 mg IV/IM for acute dystonia
- Benzodiazepines (lorazepam 1-2 mg IV) for akathisia or seizures
- For seizures: standard benzodiazepine protocol, avoid medications that further prolong QT
Monitoring Duration
- If QT interval >500 ms: continue cardiac monitoring until QT normalizes AND patient is clinically well 2
- If QT <500 ms but prolonged from baseline: monitor minimum 16 hours
- Monitor for delayed cardiac effects - case reports document cardiac arrest even after initial stabilization 2
Critical Pitfalls to Avoid
Do not discharge patients early - one reported fatality occurred after cardiac arrest despite initial stabilization, emphasizing the need for extended observation 2. The Australian experience with four severe overdose cases in 2004-2005 revealed that cardiac toxicity can be more severe than anticipated from therapeutic use data.
Do not use typical antipsychotics or other QT-prolonging agents for agitation management - this compounds the cardiac risk.
Do not rely on hemodialysis as a rescue intervention - it is explicitly ineffective for amisulpride removal 1.
Context: Therapeutic vs. Toxic Doses
At therapeutic doses (400-800 mg/day oral for schizophrenia, 5-10 mg IV for PONV), amisulpride demonstrates a satisfactory safety profile 4. However, the threshold for serious toxicity appears to be doses exceeding 1200 mg/day orally 1. The dramatic difference between therapeutic and toxic effects underscores the importance of dose verification in suspected overdose cases.